COMP <GO>
MEDP vs CRL // RETURN ON INVESTED CAPITAL (ROIC)
Medpace Holdings Inc. (NASDAQ) VS. Charles River Laboratories International Inc. (NYSE) • 15-METRIC TALLY: MEDP 9
— CRL 3
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MEDP
LAST: $652.01 (-3.77%) • MKT CAP: $18.24B
roic
27.90%
LAST: $359.41 (-4.44%) • MKT CAP: $17.16B
roic
0.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MEDP VS. CRL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MEDP | CRL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 27.90% | 0.40% | +27.50 | MEDP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.0x | 95.0x | -61.00 | MEDP | /valuation <GO> |
| Free Cash Flow Yield | 3.60% | 3.10% | +0.50 | MEDP | /fcf-yield <GO> |
| Operating Margin | 21.10% | 0.60% | +20.50 | MEDP | /operating-margins <GO> |
| Net Profit Margin | 17.80% | -3.60% | +21.40 | MEDP | /net-margins <GO> |
| Revenue Growth (YoY) | 20.00% | -0.90% | +20.90 | MEDP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.13 | 3.65 | +5.48 | MEDP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | MEDP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 62.3 | -9.90 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.3x | 23.0x | +12.30 | CRL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.24B | $17.16B | $1.08B | MEDP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MEDP REV | CRL REV | MEDP GROSS % | CRL GROSS % | MEDP FCF | CRL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $4.02B | — | — | $681.9M | $557.0M |
| FY 2024 | $2.11B | $4.05B | — | — | $572.3M | $552.3M |
| FY 2023 | $1.89B | $4.13B | — | — | $348.5M | $498.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MEDP // BETA 1.00
CRL // BETA 1.15